Protagonist Therapeutics Logo
US74366E1029
A2AP32
PTGX

Protagonist Therapeutics

Previsión

El precio objetivo medio de los analistas es de 159,79 € (+44,42 %). La mediana es de 157,66 € (+42,50 %).

Comprar
  26
Mantener
  0
Vender
  0

Debates en la comunidad

Todavía no hay ninguna discusión sobre este activo.

Iniciar debate

  • Protagonist Therapeutics after approvals: over $1 billion cash, $300 million buyback and broad oral pipeline

    Protagonist Therapeutics sees its peptide platform validated by the approvals of Icotrokinra and MIMRYLO/Rusfertide and reports a pro-forma cash balance of over $1 billion following a $275 million milestone payment. Management announced a $300 million share repurchase program but emphasized that research and development remain the highest priority. The company is advancing several oral programs (IL‑23/IL‑17/IL‑4, obesity triple agonist) and is selectively seeking partnerships for late-stage development and commercialization. » Más en de.investing.com


  • Protagonist Therapeutics announces $300 million share buyback and plans to use licensing revenue to fund pipeline

    At the Citigroup Biopharma Summit, Protagonist Therapeutics highlighted its shift to a commercial phase after two approvals and reported strong launch data for ICOTYDE and positive data for MIMRYLO (Rusfertide). The company plans a $300 million share repurchase program and intends to use future licensing income to finance R&D and enhance shareholder returns. The pipeline focuses on oral peptide therapeutics in immunology, obesity and rare diseases, with Protagonist seeking early partnerships and aiming to advance programs to proof-of-concept. Near-term success and valuation depend on sustained sales of the approved products, progress of the oral candidates and favourable partnerships. » Más en de.investing.com


  • Protagonist Therapeutics approves $300 million share buyback program

    The board of directors of Protagonist Therapeutics has approved a share buyback program of up to $300 million, to be funded from cash on hand, cash equivalents, marketable securities and license and collaboration payments. As of June 30, 2026, the company had $849.5 million in cash; additional payments from Takeda totaling $275 million are expected in Q4 2026. The timing and amount of repurchases will depend on market conditions, the share price and license and milestone payments; the program does not obligate the company to buy any specific number of shares. Protagonist generates revenue from royalties under partnerships for MIMRYLO (Rusfertide) with Takeda and ICOTYDE (Icotrokinra) with Johnson & Johnson. » Más en de.investing.com


  • Protagonist Therapeutics receives $275M after MIMRYLO FDA approval, opts for royalties

    FDA approval of MIMRYLO (rusfertide) triggered $275 million in payments to Protagonist Therapeutics (a $200M opt-out fee plus a $75M approval milestone). Under the April opt-out, Protagonist agreed to tiered royalties of 14%–29% on worldwide net sales and remains eligible for up to $875 million of additional milestones, while Takeda assumes global development and commercialization. The Phase 3 VERIFY trial showed 76.9% response with MIMRYLO plus standard care versus 32.9% for placebo, but Protagonist relinquishes pricing and launch control and relies on Takeda for market access. The royalty deal provides non-dilutive capital and lower execution risk but limits upside compared with a retained profit share and depends on broad payer and physician adoption. » Más en finance.yahoo.com


  • Protagonist Therapeutics receives $275 million from FDA approval of MIMRYLO (Rusfertide)

    The FDA has approved MIMRYLO (Rusfertide) for treatment of erythrocytosis in adults with polycythemia vera, allowing Takeda to commercialize the drug and triggering immediate payments of $275 million to Protagonist (a $200 million opt‑out plus a $75 million approval milestone). Protagonist can also receive up to $875 million in additional milestones and tiered royalties of 14–29% on worldwide net sales. Approval was based on the phase 3 VERIFY study, in which 76.9% of patients treated with MIMRYLO achieved a clinical response versus 32.9% in the placebo group. The most common adverse events were injection‑site reactions (56%) and anemia (16%); treatment is administered weekly by subcutaneous injection. » Más en de.investing.com

En 2023, Protagonist Therapeutics ya ha pagado 180,12 € en dividendos. El último pago fue en abril de 2023.

Datos financieros

En el último trimestre, Protagonist Therapeutics tuvo unos ingresos de 242,26 M € y un beneficio neto de 194,24 M €

(EUR) septiembre de 2026
YoY
Ingresos 242,26 M 5933,59 %
Beneficio bruto 241,29 M 5909,40 %
Beneficio neto 194,24 M 679,44 %
EBITDA 200,03 M 702,23 %

Datos fundamentales

Métrica Valor
Capitalización bursátil
7221,35 M €
Número de acciones
65,27 M
Máximo/mínimo de 52 semanas
146,55 € - 70,17 €
Dividendos No
Beta
1,79
Ratio P/E
23,54
Ratio PEG
-0,01
Ratio P/B
7,43
Ratio P/S
14,36

Perfil de la empresa

Protagonist Therapeutics, Inc., una empresa biofarmacéutica, descubre y desarrolla fármacos terapéuticos basados en péptidos para abordar la hematología y los trastornos sanguíneos, así como enfermedades inflamatorias e inmunomoduladoras. Está desarrollando rusfertide (PTG-300), un mimético de hepcidina inyectable que se encuentra en ensayos clínicos de fase II para el tratamiento de pacientes con policitemia vera y hemocromatosis hereditaria, así como para el tratamiento de otros trastornos sanguíneos; PN-943, un péptido antagonista oral y específico de la integrina alfa-4-beta-7 que se encuentra en ensayos clínicos de fase II para el tratamiento de la enfermedad inflamatoria intestinal (EII); y PN-235, un antagonista oral y específico del receptor de la interleucina-23 para el tratamiento de la EII y de indicaciones distintas a la EII. La empresa tiene un acuerdo de licencia y colaboración con Janssen Biotech, Inc. Protagonist Therapeutics, Inc. se fundó en 2006 y tiene su sede en Newark, California.

Nombre
Protagonist Therapeutics
CEO
Dinesh V. Patel
Sede Newark, ca
Estados Unidos
Sitio web
Sector
Materiales
Industria
Productos químicos
Salida a bolsa
11/08/2016
Empleados 141

Símbolos bursátiles

Bolsa Símbolo
NASDAQ
PTGX
🍪

Parqet  usa cookies. Más información